An open-label phase I comparator-controlled clinical trial to assess tolerability and pharmacokinetics of IHL-675 A a fixed dose combination of cannabidiol plus hydroxychloroquine in healthy volunteers

Abstract This was a phase I randomised comparator controlled clinical trial that assessed the pharmacokinetics (PK), and tolerability of IHL-675 A, a fixed dose combination (FDC) of cannabidiol (CBD) and hydroxychloroquine sulfate (HCQ), compared to the reference listed drugs Epidiolex (CBD) and Pla...

Full description

Saved in:
Bibliographic Details
Main Authors: George Williams Mbogo, Pia Kroner, Rosemarie Walsh, Jonathan Newchurch, Mark Robert Bleackley
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-04573-5
Tags: Add Tag
No Tags, Be the first to tag this record!